Memorial Sloan Kettering Cancer Center
The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).
Inclusion criteria - Cohorts A and B Demographic Characteristics a. Be \> 18 years of age General Criteria 1. Have Karnofsky Performance Status (KPS) of ≥ 70% or ECOG Performance Status of ≤ 2 2. Is able to understand and provide written informed consent for the trial prior to any study-specific procedures and is willing to comply with scheduled visits, treatment plans, procedures and laboratory tests. A legally authorized representative may consent on behalf of a subject who is otherwise unable to provide informed consent, if acceptable to and approved by the institutional review board.…
Mirdametinib is a highly selective and potent, non-ATP-competitive oral inhibitor of MEK1 and MEK2 kinases